FDAnews
www.fdanews.com/articles/126357-santarus-patents-on-zegerid-ruled-invalid

Santarus Patents on Zegerid Ruled Invalid

April 20, 2010
A federal court has ruled that five patents on Santarus’ heartburn drug Zegerid are invalid due to obviousness, a move that could pave the way for generic versions of the drug to enter the market. The company’s patents on Zegerid (omeprazole/sodium bicarbonate) were challenged by generic drugmaker Par Pharmaceutical, according to a filing with the U.S. District Court for the District of Delaware. Santarus says it plans to appeal. The Zegerid patents expire July 15, 2016.
Washington Drug Letter